Home > Insider Trading > Filing (0000919574-19-002943)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1103021	Biodelivery Sciences International Inc	BDSI	Pharmaceutical Preparations (2834)	352089858

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1511900	Ltd Fund Master Healthcare Broadfin	20 Genesis Close Ansbacher House, Second Floor, 1344 Grand Cayman E9 KY1-1108	Yes	No	No	No
1511901	Broadfin Capital, Llc	300 Park Avenue 25Th Floor New York NY 10022	Yes	No	No	No
1601692	Kevin Kotler	C/O Broadfin Capital, Llc 300 Park Avenue, 25Th Floor New York NY 10022	Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-04-11	2,000,000	$5.00	4,281,943	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Acquisiton	2019-04-11	360	$10,000.00	2,000,000	$1.80

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,840	2019-04-11		No	4	C	Indirect

Footnotes

The securities are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC and may be deemed to be beneficially owned by Kevin Kotler, managing member of Broadfin Capital, LLC. Each of Broadfin Capital, LLC, Broadfin Healthcare Master Fund, Ltd. and Kevin Kotler disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and affirmatively disclaim being a "group" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
The securities include 3,124 shares of Common Stock acquired by Mr. Kotler as a result of the vesting of Restricted Stock Units granted to the Mr. Kotler on August 1, 2018 under the Issuer's 2011 Equity Incentive Plan, as amended.
The securities may (i) only be converted after Shareholder Approval is granted, and (ii) not be converted if, after such conversion, the Reporting Person would beneficially own, as determined in accordance with Section 13(d) of the Act, more than 9.98% of the Common Stock outstanding immediately after giving effect to such conversion. The securities do not have an expiration date, but the issuer may force conversion of the securities, subject to certain limitations.